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ISCOMATRIX vaccines mediate CD8+ T-cell
cross-priming by a MyD88-dependent
signaling pathway
Nicholas S Wilson1, Becky Yang1, Adriana Baz Morelli2, Sandra Koernig2, Annie Yang1, Stefanie Loeser1,
Denise Airey2, Larissa Provan2, Phil Hass1, Hal Braley2, Suzana Couto1, Debbie Drane2, Jeff Boyle2,
Gabrielle T Belz3, Avi Ashkenazi1 and Eugene Maraskovsky2
Generating a cytotoxic CD8+ T-cell response that can eradicate malignant cells is the primary objective of cancer vaccine
strategies. In this study we have characterized the innate and adaptive immune response to the ISCOMATRIX adjuvant, and the
ability of vaccine antigens formulated with this adjuvant to promote antitumor immunity. ISCOMATRIX adjuvant led to a rapid
innate immune cell response at the injection site, followed by the activation of natural killer and dendritic cells (DC) in regional
draining lymph nodes. Strikingly, major histocompatibility complex (MHC) class I cross-presentation by CD8a+ and CD8a  DCs
was enhanced by up to 100-fold when antigen was formulated with ISCOMATRIX adjuvant. These coordinated features enabled
efﬁcient CD8+ T-cell cross-priming, which exhibited prophylactic and therapeutic tumoricidal activity. The therapeutic efﬁcacy
of an ISCOMATRIX vaccine was further improved when co-administered with an anti-CD40 agonist antibody, suggesting that
ISCOMATRIX-based vaccines may combine favorably with other immune modiﬁers in clinical development to treat cancer.
Finally, we identiﬁed a requirement for the myeloid differentiation primary response gene 88 (MyD88) adapter protein for both
innate and adaptive immune responses to ISCOMATRIX vaccines in vivo. Taken together, our ﬁndings support the utility of the
ISCOMATRIX adjuvant for use in the development of novel vaccines, particularly those requiring strong CD8+ T-cell immune
responses, such as therapeutic cancer vaccines.
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Tumor-associated antigens can be of oncogenic viral origin or derived
from self-neoantigens that are mutated, overexpressed or ectopically
expressed by tumor cells.1 The potential immunogenicity of tumor-
associated antigen has stimulated decades of research to develop
efﬁcacious therapeutic cancer vaccines. The effectiveness of a cancer
vaccine hinges on its ability to induce cytotoxic CD8+ T cells that can
inﬁltrate primary tumors, eradicate disseminated malignant cells and
protect patients from relapse.2,3 Therapeutic cancer vaccines are
typically comprised of a well-vetted TA-Ag and an immune mod-
ulator, such as an adjuvant, to condition the microenvironmental
context and boost the immunogenic potential of the TA-Ag, and to
facilitate its major histocompatibility complex (MHC) class I pre-
sentation by antigen-presenting cells to promote cytotoxic T-lympho-
cyte (CTL) cross-priming.4 Mechanisms underlying most vaccine
adjuvants are incompletely understood; however, include prolonged
half-life of the antigen, enhanced innate cell inﬁltration into the site
of antigen deposition, improved antigen presentation by antigen-
presenting cells and increased production of immunomodulatory
cytokines and chemokines.5 However, most clinically used adjuvants
(for example: alum, Montanide, MPL and MF59) are limited in their
ability to elicit CD8+ CTL responses.6 The paucity of adjuvants that
can promote tumor-speciﬁc CD8+ T-cell responses has led to the
evaluation of many novel adjuvant technologies. ISCOMATRIX adju-
vant (CSL Limited, Parkville, Australia) is a saponin-based particulate
adjuvant (which forms cage-like structures approximately 40nm in
diameter).7 In pre-clinical models, ISCOMATRIX vaccines have been
demonstrated to generate broad humoral and cellular immune
responses; importantly, this includes CD8+ T-cell immunity.8 How-
ever, the mechanistic details of how ISCOMATRIX vaccines achieve
CD8+ T-cell responses in vivo have not been fully elucidated.
Dendritic cells (DCs) present antigenic peptides to CD4+ T cells via
MHC class II molecules and CD8+ T cells through MHC class I
molecules. In most instances MHC class I presentation is restricted to
endogenously derived proteins; however, certain DC subsets possess
Received 16 December 2010; revised 7 July 2011; accepted 10 July 2011; published online 6 September 2011
1Department of Molecular Oncology, Genentech Inc., South San Francisco, CA, USA; 2CSL Limited, Parkville, Victoria, Australia and 3Immunology Division, The Walter and Eliza
Hall Institute of Medical Research, Parkville, Victoria, Australia
Correspondence: Dr A Ashkenazi, Department of Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
E-mail: ashkenazi.avi@gene.com or Associate Professor E Maraskovsky, CSL Limited, 45 Poplar Road, Parkville, Melbourne, Victoria 3052, Australia.
E-mail: eugene.maraskovsky@csl.com.au
Immunology and Cell Biology (2012) 90, 540–552
& 2012 Australasian Society for Immunology Inc. All rights reserved 0818-9641/12
www.nature.com/icbthe ability to deliver exogenously derived proteins into the MHC class
I presentation pathway, a process termed cross-presentation.4,9 In
mice, cross-presentation has been identiﬁed as a feature of the
CD8a+ subset of lymphoid organ DCs (CD8 DCs hereafter),10–13
although a second population of tissue-derived CD103+ DCs
may support CD8+ T-cell cross-priming during certain pathogenic
infections.14,15
Pathogen-associated antigens captured by antigen-presenting cells
are generally associated with pathogen-associated molecular patterns
that are detected by pattern recognition receptors, such as those of the
toll-like receptor (TLR) and inﬂammasome pathways.16,17 Under these
conditions, antigen cross-presentation and appropriate DC activation
favor CD8+ T-cell cross-priming.4 In contrast, tumor-associated anti-
gen can be cross-presented in the absence of appropriate immune
activation, and in the context of tumor-mediated immune suppres-
sion.18,19 As such, DCs cross-presenting tumor-associated antigen
often fail to mount an effective antitumor CD8+ CTL immune
response. Cancer vaccine strategies likely require an adjuvant to
potentiate the immunogenicity of the vaccine antigen by concomi-
tantly activating cross-presenting DCs.3 However, immune activation
without efﬁcient cross-presentation may result in a failed or subopti-
mal antitumor response. Therefore, a desirable feature of an immune
adjuvant is to combine both immune modulation and efﬁcient
antigen delivery into the MHC class I cross-presentation pathway.
In this study we have characterized the innate and adaptive immune
responses elicited by ISCOMATRIX vaccines in mice. We propose that
t h ei n t e g r a t e dc a p a c i t yo fI S C O M A T R I Xa d j u v a n tt oe n h a n c ea n t i g e n
cross-priming, combined with immune activation, supports its clinical
development as a cancer vaccine adjuvant.
RESULTS
ISCOMATRIX adjuvant promotes an innate immune response
in vivo
The innate immune response to injected ISCOMATRIX adjuvant was
evaluated using the sterile subcutaneous air-pouch technique.20
Gr1high neutrophils rapidy accumulated in the air-pouch within 4h
of ISCOMATRIX adjuvant administration, Ly6Chigh monocyte inﬁl-
tration peaked at 16h, relative to phosphate-buffered saline (PBS)-
injected control air-pouches (Figure 1a). The inﬂux in neutrophils and
monocytes correlated with a dramatic increase in the number of
myeloid (CD11bhigh) cells recovered from the air-pouch exudate (data
not shown). To assess the local cytokine and chemokine response to
ISCOMATRIX adjuvant, immune cell inﬁltrates were isolated and
cultured overnight. Interleukin (IL)-5, monocyte chemotactic protein-
1 and macrophage-colony-stimulating factor (CSF) levels were
signiﬁcantly elevated in the supernatant collected from immune cells
obtained from ISCOMATRIX adjuvant-treated mice (Figure 1b). No
signiﬁcant differences were observed in the other chemokines or
cytokines analyzed (data not shown).
We next characterized the innate immune cell response in the
brachial (draining) and inguinal (non-draining) lymph nodes (LNs).
Correlating with an overall increase in cellularity (Supplementary
Figure 1A), the number of natural killer (NK) cells, NK T cells,
monocytes and neutrophils were elevated in the draining LN (DLN),
compared with the non-DLN (Figure 1c, and Supplementary Figure
1B). To evaluate innate immune cell activation, we examined NK cell
interferon (IFN)-g—production and CD69 upregulation following a
single dose of ISCOMATRIX adjuvant. IFN-g-producing NK cells
were detected in the DLN within 3h of subcutaneous adjuvant
delivery, and peaked at 24h (Figure 1d). NK cell IFN-g production
correlated with increased surface expression of the early activation
marker, CD69 (Figure 1e). Increased CD69 expression was restricted
to the DLN, and was also elevated on other immune cell populations
including B cells and DCs (data not shown). Given the ability of
ISCOMATRIX adjuvant to recruit a local inﬂammatory response, we
sought to investigate adaptive immune responses to ISCOMATRIX
adjuvant formulated with two model vaccine antigens, given as a
prime and boost regimen.
ISCOMATRIX vaccines facilitate cellular and humoral immune
responses
To characterize the adaptive immune response to ISCOMATRIX
vaccines, we utilized antigens with well-deﬁned H-2Kb-restricted
MHC class I epitopes in C57Bl6 mice: ovalbumin (OVA) and a fusion
protein based on herpes simplex virus (HSV) coat proteins glycopro-
tein B (HSV-1) and D (HSV-2) (gB:gD). The endogenous antigen-
speciﬁc CD8+ T-cell response was quantiﬁed in the spleen following a
prime, or prime-boost vaccination regimen (Figure 2a, schematic). The
percentage of vaccine antigen-speciﬁc IFN-g-producing CD8+ Tc e l l si s
shown relative to percentage obtained with the day  7, 0 vaccination
protocol (Figures 2b and c). The percentage of antigen-speciﬁc IFN-g-
producing CD8+ T cells was routinely between 3 and 8% of the
endogenous CD8+ T cells (Supplementary Figure 2A). This percentage
correlated with the number of CD44high OVA-speciﬁc CD8+ Tc e l l s
quantiﬁed using an H-2Kb-SIINFEKL tetramer (Supplementary Figures
2B and 2C). The humoral response was evaluated with the same dosing
regimens used to assess the CD8+ T-cell response (Figure 2a, sche-
matic). OVA-speciﬁc antibody titers were compared in sera collected
from naive mice or 7 or 28 days after the ﬁnal vaccination. Initial titers
were highest 7 days after the  28, 0 regimen; however, total levels were
comparable after 28 days with all dosing combinations (Figure 2d).
Depending on the challenge model, cytotoxic CD8+ T-cell priming
can require assistance by CD4+ Th e l p e r( T H) cells.21,22 To investigate
whether CD4+ TH participated in ISCOMATRIX adjuvant-mediated
cellular immunity, we compared effector and recall CD8+ T-cell
responses in wild type and MHC class II-deﬁcient mice, which lack
CD4+ T cells.23 MHC class II-deﬁcient mice generated 60% fewer
antigen-speciﬁc IFN-g-producing CD8+ T cells compared with wild-
type control mice (Figure 2e). Consistent with this ﬁnding, the CD8+
T-cell recall response was severely compromised in MHC class II-
deﬁcient mice (Figure 2f). Vaccinated MHC class II-deﬁcient mice
also failed to develop vaccine-antigen-speciﬁc antibodies (Figure 2g).
Antitumor responses require components of innate and adaptive
immunity
We next evaluated the cytotoxic activity of CD8+ T cells generated by
an ISCOMATRIX vaccine by monitoring the lysis of target cells pulsed
with SIINFEKL peptide in pre-vaccinated versus control (OVA)-
treated animals (Figure 3a). To conﬁrm the antitumor activity of
the vaccine antigen-speciﬁc CTLs, we used the B16 melanoma tumor
challenge model.24 In all, 80% of vaccinated mice remained tumor-
free after 125 days, as compared with a 100% tumor incidence in mice
that received ISCOMATRIX alone (control) (Figure 3b). All tumor-
free mice rejected a subsequent challenge of OVA-expressing mela-
noma cells but succumbed to parental B16 tumor cell growth (data
not shown). To evaluate the impact of an ISCOMATRIX vaccine in the
therapeutic tumor model, mice were inoculated with OVA-expressing
melanoma cells 5 days before prime and boost vaccination (Figure 3c).
A signiﬁcant delay in tumor growth was observed only in the
vaccinated cohort, which correlated with improved survival, although
all mice eventually succumbed to tumor burden (Figure 3d). ISCO-
MATRIX or OVA alone did not extend survival, as compared with
ISCOMATRIX vaccines promote CD8+ T-cell cross-priming
NS Wilson et al
541
Immunology and Cell Biologyuntreated animals (Supplementary Figure 3A). We next assessed
whether ISCOMATRIX vaccines could combine with an immune
modiﬁer to augment the therapeutic antitumor activity. Anti-CD40
agonists are recognized as potent immune modiﬁers, and as such,
represent an attractive immunotherapy in treating neoplastic dis-
ease.25,26 We found that the anti-CD40 antibody, FGK45, combined
effectively with an ISCOMATRIX vaccine to signiﬁcantly extend
survival beyond what was achieved with vaccine or anti-CD40 plus
antigen formulations alone (Figure 3e).
To evaluate the contribution of innate and adaptive immune cell
populations in ISCOMATRIX vaccine-mediated tumor protection, we
depleted CD8+,C D 4 + or NK cells during the prime and boost
vaccinations. Vaccine-mediated tumor protection was severely atte-
nuated when T cell or NK cell populations were depleted (Figure 3f).
To test the hypothesis that cross-primed CD8+ T cells could confer
tumor protection in our model, we adoptively transferred CD8-
enriched and CD8-depleted splenocyte fractions from previously
vaccinated mice into naive recipients. All mice were challenged 1
day later with B16-OVA melanoma cells (Figure 3g). Only the CD8+
splenocyte fraction was able to provide tumor protection in 40% of
the naive recipients. Taken together, these results indicate that ISCO-
MATRIX vaccines require the coordinated function of the innate and
adaptive response to generate an antitumor CTL response in vivo.
DCs are required for NK cell activation and CD8+ T-cell immunity
in response to an ISCOMATRIX vaccine
DCs are potent stimulators of naı ¨ve T cells and NK cells, and as such,
provide a critical link between innate and adaptive immunity.4,27,28 To
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Figure 1 ISCOMATRIX adjuvant activates innate immune cells in vivo.( a) Immune cell inﬁltrates were gated on the myeloid marker CD11b. Monocyte
(CD11b+Ly6C+) and neutrophil (CD11b+Gr1+) recruitment into subcutaneous air-pouches was evaluated 4, 16 and 24h following subcutaneous ISCOMATRIX
adjuvant (IMX) administration. Proﬁles are representative for n¼3–6 mice per time-point. (b) Levels of IL-5, monocyte chemotactic protein-1 a and
macrophage CSF (macrophage-CSF) detected in cultured air-pouch immune exudates. Error bars show the s.e.m. (n¼3 per group). Student’s t-test was used
to calculate statistical signiﬁcance. (c) Time-course of NK cell accumulation in the DLN (brachial) and non-DLN (inguinal) following subcutaneous IMX
injection. (d) Ex vivo NK cell IFN-g production in the DLN and non-DLN after IMX administration. Error bars represent the s.e.m. (n¼4–8 individual LN per
time-point). (e) Representative proﬁles showing NK cell expression of CD69 in the DLN of naı ¨ve or 24h after IMX injection. No increase in CD69 expression
was observed on NK cells, or other cell populations, from the non-DLN (data not shown). All results are representative of at least two independent
experiments.
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Immunology and Cell Biologyevaluate the importance of DCs for vaccine-mediated CD8+ T-cell
cross-priming, we utilized transgenic mice expressing the diphtheria
toxin receptor (DTR) fused with green ﬂuorescent protein under
control of the DC-associated CD11c promoter (CD11c-DTR).29
Recipient mice were reconstituted with bone marrow from CD11c-
DTR transgenic (Figure 4a, schematic). This rendered DTR-expressing
CD11c+ cells sensitive to diphtheria toxin (DT) (Figure 4b). Notably,
radio-resistant Langerhans cells,30,31 represented the green ﬂuorescent
protein-negative CD11c-expressing cells in DLN of the chimeric mice.
CD11c+ DC ablation signiﬁcantly impaired the generation of antigen-
speciﬁc CD8+ T cells (Figure 4c and Supplementary Figure 4A).
Depletion of CD11c-expressing cells had no effect on ISCOMATRIX
adjuvant-mediated NK cell accumulation in the DLN but signiﬁcantly
reduced NK cell IFNg production (Figure 4d and data not shown).
Given the dependence on DCs for ISCOMATRIX adjuvant-mediated
NK cell and CD8+ T-cell immune responses, we next sought to
evaluate the effect of ISCOMATRIX adjuvant on DC activation
in vitro and in vivo.
ISCOMATRIX adjuvant administration results in potent DC
activation in vivo
A characteristic feature of TLR-induced DC activation is increased cell
surface expression of T-cell co-stimulatory molecules and MHC class
II.13,32 To establish whether ISCOMATRIX adjuvant directly activated
DCs, we generated DCs in vitro using the FMS-like tyrosine kinase 3
(Flt3) ligand culture system.33,34 Compared with TLR4 (lipopolysac-
charide, LPS) or TLR9 (CpG) stimulation, ISCOMATRIX adjuvant
failed to induce CD40, CD69, CD80 or MHC class II expression
(Figure 5a and data not shown). A modest increase in CD86 was
observed but to a lesser extent than TLR4 or 9 stimulation.
Similar results were obtained with DCs generated with granulocyte-
macrophage CSF and IL-4 (data not shown). Plasmacytoid DCs in
the Flt3L-treated cultures did not respond to ISCOMATRIX
adjuvant (data not shown). Consistent with the lack of phenotypic
activation, ISCOMATRIX adjuvant failed to induce pro-inﬂammatory
cytokine production by macrophages or DCs, as compared with
lipopolysacaride (LPS) stimulation (Supplementary Figure 5A and
data not shown).
DC activation is considered a key event in T-cell priming.35 Given
our in vitro results, we questioned whether ISCOMATRIX adjuvant
injection caused DC activation in vivo. DCs isolated from the DLN
24h post-ISCOMATRIX adjuvant administration were evaluated for
activation marker expression (Figure 5b). In contrast to our in vitro
results, CD8+CD205+ DCs (CD8 DCs) showed consistent upregula-
tion of CD40, CD80, CD86 and MHC class II. Activation markers on
CD205 CD8  DCs (double negative, DN DCs) or tissue-derived
migratory CD8 CD205+ DCs (MigDCs) did not signiﬁcantly change
with treatment. Plasmacytoid DCs in the DLN showed modest
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Figure 2 Cellular and humoral immune responses to ISCOMATRIX vaccines are dependent on CD4+ T-cell help. (a) Schematic showing the dosing regimen
used to evaluate vaccine antigen-speciﬁc CD8+ T cell and antibody response. (b)I F N - g production by endogenous OVA-speciﬁc CD8+ T cells was determined
in the spleen 7 days after the boost vaccination. (c)I F N - g production by endogenous gB (HSV-1)-speciﬁc CD8+ T cells was determined in the spleen 7 days
after the boost vaccination. Results in (b, c) are expressed relative to the response obtained with a day  7, 0-dosing regimen. Mean values are expressed
±s.e.m. Student’s t-test was used to calculate statistical signiﬁcance. (d) OVA-speciﬁc antibody titers (total IgG) in serum collected from mice vaccinated
with the dosing protocols shown in (a). OVA-speciﬁc titers were quantiﬁed 7 or 28 days after the ﬁnal vaccine dose. (e) OVA-speciﬁc CD8+ T-cell responses
were compared in wild type (WT) and MHC class II-deﬁcient mice (MHC II KO) vaccinated on days  7, 0. (f) The OVA-speciﬁc ‘recall’ CD8+ T-cell response
was assessed using a 5-day ex vivo re-stimulation protocol. (g) OVA-speciﬁc IgG titers in serum collected from naı ¨ve WT or MHC II KO vaccinated with two
different vaccine dosing regimens. All results are representative of at least two or more independent experiments. ‘Student’s’ t-test was used to calculate
statistical signiﬁcance.
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Immunology and Cell Biologyincreases in activation marker expression (data not shown). DC
activation was not evident in the spleen or in the non-DLN (data
not shown). In comparison with LPS administration, ISCOMATRIX
adjuvant induced similar or greater activation marker upregulation by
the DLN CD8 DCs (Figure 5c). Consistent with immune cell activa-
tion, systemic cytokines were detected in the serum of ISCOMATRIX
adjuvant-treated mice; although at much lower levels compared with
LPS-treated mice, with the exception of IL-5 (Figure 5d). In the DLN,
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Immunology and Cell Biologyelevated levels of IL-6 and the IL-6-type cytokine family member
leukemia inhibitory factor,36 along with monocyte chemotactic pro-
tein-1, macrophage-CSF and tumor necrosis factor-a (TNF-a)w e r e
detected (Supplementary Figure 6a).
ISCOMATRIX adjuvant facilitates antigen cross-presentation by
CD8 and non-CD8 DCs
Given the ability of ISCOMATRIX adjuvant to promote DC activation
and provide a pro-inﬂammatory milieu in vivo,w en e x ta s s e s s e di t s
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Figure 4 CD11c-expressing cells are required for ISCOMATRIX adjuvant -mediated NK cell and CD8+ T-cell responses. (a) Schematic showing the generation
of CD11c-DTR mice, and the CD11c+ depletion protocol used during the prime and boost IMX vaccine regimen. (b) Representative proﬁle showing the
depletion of radiosensitive CD11c/DTR-green ﬂuorescent protein-expressing DCs at the time the antigen-speciﬁc CD8+ T-cell immune responses were
quantiﬁed. (c) CD11c-DTR mice were either treated with PBS or DT 1 day before the prime vaccine dose, and then three times per week. The OVA-speciﬁc
CD8+ T-cell response was assessed ex vivo in the spleen 7 days after the boost vaccination. The magnitude of the response is shown relative to the PBS-
treated cohort ±s.e.m. Results are pooled from two separate experiments. (d) CD11c-DTR mice were treated with PBS or DT  3a n d 1d a y sb e f o r eas i n g l e
dose of ISCOMATRIX adjuvant. Ex vivo NK cell IFN-g production was measured in the DLN after 24h. The magnitude of the response is shown relative to the
PBS-treated cohort, ±s.e.m. The results are representative of at least two separate experiments. Student’s t-test was used to calculate statistical signiﬁcance.
Figure 3 The antitumor response mediated by ISCOMATRIX vaccines requires components of innate and adaptive immunity. (a) The CTL response was
evaluated in animals that received the ISCOMATRIX (IMX) vaccine or antigen (OVA) alone on day  7, 0. SIINFEKL-pulsed CFSEhigh-labeled target cells were
injected intravenously on day +7, and speciﬁc-lysis was evaluated ex vivo 4h later by ﬂow cytometry. Speciﬁc lysis was calculated relative to a control (non-
pulsed) CFSElow-labeled cell population. The mean speciﬁc lysis is shown ±s.e.m. Student’s t-test was used to calculate statistical signiﬁcance.
(b) Tumor incidence in mice that received IMX vaccine (n¼9) or IMX alone (control, n¼10) on day  7, 0. All animals were challenged 7 days after boost dose
with 1.5 105 B16:OVA melanoma cells. (c) Tumor cells were inoculated in mice 5 days before receiving the IMX vaccine (vaccine) or IMX alone (control) on
day 5 and 12. Tumor volumes were monitored until the ﬁrst tumor reached the 3000mm3, which was nominated as the survival end-point. ‘Student’s’ t-test
was used to calculate statistical signiﬁcance; n¼10 per group. (d) Kaplan–Meier curves showing survival end-points for the cohorts in (c)( Po0.002 by the
log-rank test) (n¼10 per group). (e) Tumor cells were inoculated into mice 5 days before the indicated vaccination regimens (day 5 (prime) and 12 (boost)).
Kaplan–Meier curves showing survival end-points for each cohort (n¼10 per group; vaccine versus anti-CD40+vaccine¼Po0.002 by the log-rank test). (f)
Mice were administered anti-CD4, anti-CD8 or anti-asialo-GM1 (anti-asialo) on days  8,  5,  2, +1 and +4 during the day  7, 0 vaccine regimen. Mice
were challenged on day +7 with 1.5 105 B16:OVA cells and tumor incidence was monitored. (g) CD8-enriched or CD8-depleted spleen cell fractions from
pre-vaccinated mice were adoptively transferred into naı ¨ve recipients. After 1 day of adoptive transfer, mice were challenged with 5 105 B16:OVA melanoma
cells. Tumor incidence was monitored out to day 125 (n¼10–12 per group). All results are representative of two or more independent experiments.
ISCOMATRIX vaccines promote CD8+ T-cell cross-priming
NS Wilson et al
545
Immunology and Cell Biologyeffects on DC migration into DLN and MHC antigen presentation.
The increase in DLN cellularity (Supplementary Figure 1A) correlated
with a three–four-fold increase in the number of CD11cint-high DCs
at 24h, as compared with mice that had received antigen alone
(Figure 6a). To evaluate the kinetics of MHC I and II presentation,
DCs were isolated at the indicated time-points from the DLN and co-
cultured with carboxyﬂuorescein succinimidyl ester (CFSE)-labeled
OVA-speciﬁc CD8+ (OT-I) or CD4+ (OT-II) T cells (Figure 6b and
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Immunology and Cell BiologySupplementary Figure 7A). DCs from mice that were vaccinated or
received OVA antigen alone induced comparable OT-I proliferation at
3h. By contrast, at 12h there was a 100-fold difference in T-cell
proliferation by DCs from vaccinated mice. No systemic MHC class I
antigen cross-presentation was detected in the spleen of immunized
mice (Figure 6c), and MHC class II antigen presentation was only
modestly improved by formulating OVA with the ISCOMATRIX
adjuvant (Supplementary Figure 7A).
To identify the DC subset(s) cross-presenting antigen in vivo,w e
isolated by ﬂow cytometry CD8, MigDCand DN DC populations at
12, 24 and 48h after a single vaccine dose (Figure 6d). By 12h, the
CD8 DC subset dominated MHC class I cross-presentation to OT I
cells; however, by 24h the MigDC population efﬁciently cross-
presented antigen. This second wave of cross-presentation coincided
with an inﬂux of CD8 CD205int DCs into the DLN (Figure 6a and
Supplementary Figure 7b).
Given the ability of ISCOMATRIX adjuvant to facilitate the
translocation of antigen from endosomes into the cytosol of human
DCs in vitro,37 we hypothesized that cytosolic translocation of antigens
might enable cross-presentation by non-specialized DC subsets.
To evaluate this, we puriﬁed CD8 and CD4 DCs from the spleen of
naı ¨ve animals (Figure 6e). Consistent with our earlier study,11 only
CD8 DCs efﬁciently cross-presented soluble antigen to naı ¨ve CD8+ T
cells (Figure 6f). Surprisingly, CD4 DCs were even more efﬁcient than
CD8 DCs at cross-presentating soluble antigen formulated with
ISCOMATRIX adjuvant. Finally, consistent with our in vivo observa-
tion, ISCOMATRIX adjuvant did not signiﬁcantly improve
soluble antigen delivery into the MHC class II antigen presentation
(Figure 6g).
ISCOMATRIX vaccines are dependent on a myeloid differentiation
primary response gene 88 (MyD88) signaling axis in vivo
Finally, to further understand how ISCOMATRIX vaccines mediate
cellular immunity in vivo, we investigated whether CD8+ T-cell cross-
priming was dependent on adapters of the TLR and IL-1R pathway.16
Strikingly, the CD8+ T-cell response was signiﬁcantly impaired in
MyD88-deﬁcient mice (Figure 7a). By contrast, mice deﬁcient for
TIR-domain-containing adapter-inducing IFN-b (TRIF) gave a com-
parable CD8+ T-cell response to wild-type controls (Figure 7b).
Interestingly, the increased DLN cellularity following ISCOMATRIX
adjuvant administration was indistinguishable between wild-type,
TRIF or MyD88-deﬁcient mice (data not shown). NK cell IFN-g
production and vaccine antigen-speciﬁc antibody responses were also
strongly impaired in MyD88-deﬁcient mice (Supplementary Figure
8A and data not shown). To evaluate if an endogenous TLR4 ligand,
signaling through the MyD88 adapter, may reproduce this phenotype,
we assessed the vaccine-mediated CD8+ T-cell response in TLR4-
deﬁcient mice (Figure 7c).7 Unlike MyD88, TLR4 was dispensable for
ISCOMATRIX vaccine-mediated cellular responses in vivo. Interest-
ingly, MyD88-deﬁciency had no effect on vaccine antigen cross-
presentation by CD8 or MigDCs, or ISCOMATRIX-induced DC
maturation in the DLN (Figures 7d and e).
DISCUSSION
Therapeutic cancer vaccines are typically comprised of three compo-
nents: an antigen, to give speciﬁcity to the cellular response; a delivery
modality, to promote antigen capture and transfer into the MHC class
I pathway; and an immune-modulating agent, to enhance the immu-
nogenicity of the vaccine antigen.38 Therapeutic vaccines are intended
to generate CTLs that can inﬁltrate tumors and selectively eliminate
malignant cells.3
ISCOMATRIX adjuvant-based vaccines have been shown to gen-
erate robust humoral and cellular immune responses in a range of
pre-clinical models, and have a good safety proﬁle in human subjects.8
How ISCOMATRIX adjuvant facilitates immunity to co-delivered
vaccine antigens remains poorly understood. The particulate nature
of ISCOMATRIX adjuvant likely promotes efﬁcient endocytosis by
DCs; both at the injection site and by DCs in the DLNs (Figure 7f).39
The earliest detectable response to ISCOMATRIX adjuvant adminis-
tration was a rapid inﬂux of innate immune cells into the injection site
and a distinct localized cytokine and chemokine response. The initial
pro-inﬂammatory response led to innate immune cell accumulation
and activation in the LNs draining the injection site. Coordinated NK
cell and DC functionalities culminated in TH-dependent CD8+ T-cell
cross-priming. We observed that optimal vaccine antigen-speciﬁc
CD8+ T-cell responses were achieved when the boost vaccination
was delivered 7 days after the initial prime dose. This observation was
consistent with our earlier observation that DC antigen cross-pre-
sentation is restored 7 days after exposure to potent maturation
stimuli.11,13 Indeed, a boost vaccination delivered earlier than 7 days
was found to negatively impact the magnitude of the CD8+ T-cell
response (data not shown).7 Our results suggest that an accelerated
7-day interval between the prime and boost regimen may enhance
efﬁcacy, and be beneﬁcial in the instance of treating aggressively
growing tumors.
ISCOMATRIX adjuvant contains the ISCOPREP saponin, a
puriﬁed fraction of Quillaia saponin, which may alter the biophysical
properties of the endosomal membrane in cells, thereby facilitating
the cytosolic translocation of co-delivered vaccine antigens.37
Consistent with this hypothesis, ISCOMATRIX adjuvant enabled
efﬁcient MHC class I cross-presentation of a vaccine antigen in vitro
by a population of DCs that typically do not cross-present soluble
antigens. The ability of the ISCOMATRIX adjuvant to enable cross-
presentation by non-specialized DC subsets may explain the efﬁcient
MHC class I cross-presentation observed by tissue-derived
DCs trafﬁcking into DLNs from the vaccination site. Conversely,
Figure 5 In vivo DC activation and cytokine responses to ISCOMATRIX adjuvant administration. (a) Flt3L-derived DCs were cultured overnight in the
presence of IMX (5mgml  1), CpG (1mM) or LPS (1mgml  1). CD40, CD69, CD80 and CD86 upregulation (black lines) was monitored on conventional
(CD11c+CD45RA ) DCs by ﬂow cytometry, as compared with an isotype control antibody (dashed lines). (b) CD8 and double-negative (DN) lymphoid DCs
were distinguished from ‘tissue-derived’ MigDCs based on the expression of CD8 and CD205 (left dot plot).53 Right histogram; expression of CD40, CD80,
CD86 and MHC class II expression (black lines) on DCs following a single subcutaneous dose of ISCOMATRIX adjuvant, as compared with DCs isolated from
untreated DLN (gray lines). Isotype control antibody staining is shown as dashed lines. Data are representative of 3–5 experiments. (c) Activation marker
expression by CD8 DCs isolated from the DLN of untreated mice, or 24h after a subcutaneous dose of IMX (5mg) or LPS (3mg). The mean linear
ﬂuorescence (MLF) is shown on the y-axis, with isotype controls MLF values subtracted for each sample. (d) Cytokine levels in the serum collected 6 or
24h after subcutaneous IMX or LPS administration: shown are the levels of IL—1b,IL-5,IL-6, IL-10, IL-12/23(p40), granulocyte-CSF, keratinocyte
chemoattractant (KC or CXCL1), monocyte chemotactic protein-1 (MCP-1 or CCL2), macrophage inﬂammatory protein-1a (MIP-1a or CCL3) and b (MIP-1b
or CCL4), Rantes (or C) and IFN-g. Error bars show the s.e.m. (n¼6 mice per treatment group). Student’s t-test was used to calculate statistical signiﬁcance
(*Po0.05, **Po0.001, n.s., not signiﬁcant). All results are representative of two or more independent experiments.
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Immunology and Cell Biologycross-presentation by the CD205highCD11cintCD8neg DC population
identiﬁed in this study may reﬂect an intrinsic feature of a dermal
or an inﬂammatory-induced DC subset.14,15,40 Consistent with an
earlier report,30 Langerhans were not sufﬁcient for CD8+ T-cell
cross-priming in vivo. The precise identiﬁcation of the cross-present-
ing tissue-derived DC population following ISCOMATRIX
vaccine administration requires further phenotypic and functional
characterization.
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Figure 6 ISCOMATRIX adjuvant facilitates antigen entry into the MHC class I cross-presentation pathway in DCs. (a) Time-course showing the number of
CD11c+ DCs isolated from the DLN of mice injected with vaccine or OVA (antigen) alone. (b) MHC class I cross-presentation was quantiﬁed in the DLN ex
vivo after a single dose of ISCOMATRIX vaccine or OVA (antigen) alone. The CD11c+ DC fraction (490%) was puriﬁed from the DLN at the indicated times.
A total of 5 103 DCs were then co-cultured with 5 104 CFSE-labeled OT-1 CD8+ T cells. Proliferation was quantiﬁed 60h later by ﬂow cytometry. Circles
in (a)a n d( b) represent data points from independent experiments (an average of n¼4–8 DLN per sample), and bars show the pooled average. (c)M H C - I
presentation by CD11c+ DCs puriﬁed from the spleen or DLN 24h after a single ISCOMATRIX vaccine dose. OT-I proliferation was determined as in (b). (d)
Highly puriﬁed (495%) populations of CD8, DN and MigDC were puriﬁed from the DLN 12, 24 and 48h after a single vaccine dose. Cross-presentation was
assessed by co-culturing each DC population with 5 104 CFSE-labeled OT-1 cells and quantifying proliferation 60h later. (e) CD11c-enriched spleen DCs
were separated into CD8 and CD4 populations by ﬂow cytometry (495% purity). (f) CFSE-labeled OT-I T cells were co-cultured with CD8 or CD4 DCs pulsed
for 30min with OVA (antigen) alone (open symbols) or antigen+ISCOMATRIX (closed circles). Pulsed DCs were cultured with CFSE-labeled OT-I cells, and
proliferation was determined after 60h as described. (g) The same DCs used in (f) were co-cultured with CFSE-labeled CD4+ OT-II T cells. Proliferation was
quantiﬁed as described. Error bars represent the s.d. of triplicate samples. Results are representative of two or more independent experiments.
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Figure 7 ISCOMATRIX vaccines are dependent on a MyD88-signaling axis in vivo (a) CD8+ T-cell responses were compared in wild type (WT) and MyD88-
deﬁcient mice (MyD88 KO) vaccinated with an ISCOMATRIX vaccine on day  7, 0, with the magnitude of the CD8+ T-cell response shown relative to WT
mice. (b, c)S a m ea si n( a) except the CD8+ T-cell response was evaluated in TRIF or TLR4-deﬁcient mice. (d) Puriﬁed CD8 and MigDCs from wild type or
MyD88-deﬁcient (KO) mice were isolated from the DLN 24h after vaccine administration. MHC class I cross-presentation was assessed by co-culturing each
population with 5 104 CFSE-labeled OT-1 cells and quantifying proliferation 60h later, as described. (e) CD40, CD80 and CD86 expression (black lines)
was assessed for CD8 DCs isolated from the DLN of WT or MyD88 KO mice dosed with ISCOMATRIX adjuvant, compared with CD8 DCs from untreated WT
mice (gray lines). Dashed lines illustrate the median ﬂuorescence for each marker. (f) Schematic illustrating the interaction between DCs, T cells and NK
cells in the DLN following ISCOMATRIX vaccine delivery. ISCOMATRIX vaccines initiate a localized inﬂammatory response at the subcutaneous injection site,
and efﬁcient DC activation and MHC class I cross-presentation in the DLN (MyD88-independent). Although the precise DC activation signal(s) is currently
unknown, a distinct pro-inﬂammatory milieu was detected locally and systemically following ISCOMATRIX adjuvant administration. In the DLN, NK cell
activation and CD8+ T-cell cross-priming was dependent on DCs, as well as an intact MyD88 signaling network. Cross-primed CD8+ T cells exhibit potent
antitumor activity in prophylactic tumor challenge models. However, in the case of pre-established tumor burden, the effectiveness of the vaccine isl i k e l yt o
be blunted by immune suppressive networks, such as myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg) and tumor-derived factors that
prevent complete tumor eradication.
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Immunology and Cell BiologyMany therapeutic cancer vaccines have failed to achieve primary
endpoints in clinical studies.41 A likely caveat is that pre-clinical
models used to assess efﬁcacy do not adequately reproduce the
immunosuppressive mechanisms that pre-exist in cancer patients
such as; regulatory T-cell networks, immature myeloid cells and
tumor cell-derived immune suppressive factors (Figure 7f).3,18 In
addition, most current standard of care options for controlling cancer
involves chemotherapies that may impair effective cellular immune
responses.42,43 Despite this, several emerging Phase III studies indicate
that immune-modulatory strategies may have clinical activity in
certain cancer indications.44,45 Encouragingly, we have demonstrated
that the therapeutic effect of ISCOMATRIX adjuvant-based vaccines
can be enhanced through combination with clinically relevant
immune modiﬁers: melanoma (anti-CD40 agonist antibody); and in
pancreatic cancer (CpG oligodeoxynucleotide).46 A clear mechanistic
understanding of the cooperativity between these agents and ISCO-
MATRIX vaccines remains to be elucidated. For example, CD40
signaling can modulate many facets of the immune response, includ-
ing DC, macrophage and T-cell functions.25,47–49 Therefore, it is
feasible that ISCOMATRIX vaccines and CD40 agonists function
independently to activate distinct immune-signaling nodes, which
combine effectively to enhance therapeutic efﬁcacy. Importantly, our
ﬁndings suggest that the single agent activity of immunotherapeutics
may beneﬁt through combination with an ISCOMATRIX adjuvant-
based cancer vaccine.
In comparison to TLR4 agonists, ISCOMATRIX adjuvant admin-
istration produced a unique systemic and localized cytokine and
chemokine signature. This pro-inﬂammatory response was transient
and coincided with NK cell and DC activation in LNs draining the
injection site. Inconsistent with direct pattern recognition receptor
stimulation, ISCOMATRIX adjuvant failed to activate macrophages or
DCs in vitro, in contrast to TLR4 or 9 stimulation. These results
support a mechanism of indirect immune cell activation in vivo,m o s t
likely via speciﬁc cytokine cascades. To address the possibility that an
endogenous TLR ligand may indirectly facilitate immune activation,
we vaccinated mice deﬁcient for the TLR-signaling adapters MyD88 or
TRIF. Strikingly, innate and adaptive immune responses to ISCOMA-
TRIX vaccines were severely compromised in MyD88-deﬁcient mice.
We reasoned that an endogenous TLR ligand ‘danger signal’ released
upon ISCOMATRIX adjuvant administration might account for the
impaired vaccine response in MyD88-deﬁcient mice;43,50 however,
TLR4 was found to be dispensable for cellular immunity, as was IL-
1R signaling (data not shown). Instead we propose that innate
immune cells responding to ISCOMATRIX adjuvant at the injection
site initiate a cascade-localized inﬂammatory events, which culminate
in CTL cross-priming in DLNs. The exact mechanisms underlying
these events remain to be elucidated, and are the focus of continuing
research efforts. Interestingly, DC activation and cross-presentation
were MyD88-independent, lending to the possibility that MyD88-
dependence is downstream of apical inﬂammatory events but required
for DC-dependent NK cell activation and adaptive immune responses
(Figure 7f).
In conclusion, our study has characterized the immune responses to
ISCOMATRIX adjuvant in vivo. We show that ISCOMATRIX vaccines
promote signiﬁcant cross talk between the innate and adaptive
compartments, which culminate in tumorcidal CD8+ T-cell cross-
priming. These ﬁndings have clear implications for therapeutic cancer
vaccine design; however, they also implicate a novel pattern recogni-
tion receptor-independent pro-inﬂammatory pathway that may be
linked to the biophysical properties of the ISCOMATRIX adjuvant.
Taken together, our results support the clinical evaluation of combi-
nation approaches that incorporate ISCOMATRIX adjuvant-based
vaccines with immune modiﬁers to treat cancer.
METHODS
Mice
Unless otherwise stated, all C57BL/6 experimental mice were 6–8-weeks old.
Wild-type, MHC class II-deﬁcient,23 MyD88-deﬁcient,51 TRIF-deﬁcient,52
C57Bl6.TLR4(Lps-d)-deﬁcient (C3H/HEJ backcrossed n¼8 generations to
C57Bl6 background) and CD11c-DTR transgenic mice29 were maintained
under speciﬁc pathogen-free conditions. All experiments were subject to
approval by the institutional Ethics Committee according at Genentech Inc.
(South San Francisco, CA, USA), CSL Limited (Parkville, Victoria, Australia) or
the Walter and Eliza Hall Institute (WEHI, Melbourne, Victoria, Australia). All
animal work was undertaken in accordance with institutional and national
guidelines and conformed to the provisions of the Declaration of Helsinki (as
revised in Edinburgh 2000).
Air-pouch method
The air-pouch model was adapted from the method previously described.20
Brieﬂy, anesthetized mice were injected subcutaneously with 5ml of sterile air
into the intravascular area. On day 3, 2–3ml of sterile air was injected to
maintain the integrity of the air-pouch. On day 7, 5mg ISCOMATRIX adjuvant
in 100ml of PBS or PBS alone was injected into the air-pouch. At the indicated
time, animals were euthanized by CO2 inhalation and 1ml of PBS was injected
into the air-pouch. Exudates, typically 500–800ml, were collected and analyzed
for inﬁltrating immune cells. For cytokine and chemokine determinations,
inﬁltrating cells were isolated 4h after the indicated treatment, and cultured
overnight in serum-free media (Invitrogen, Carslbad, CA, USA). Supernatants
were concentrated using Amicon Ultra centrifugal ﬁlters (3kDa) (Millipore,
Billerica, MA, USA) before chemokine and cytokine analysis.
Cytokine determinations
Cytokines and chemokines were measured with the Bio-Plex cytokine assay (Bio-
Rad, Hercules, CA, USA) and analyzed with the Luminex 100 system (Luminex,
Austin, TX, USA). The full list of chemokines and cytokines included in the 32-
plex assay were: IL-1a,I L - 1 b, IL2, IL4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-
12p70, IL-13, IL-15, IL-17, IL-18, Eotaxin, granulocyte-CSF, macrophage-CSF,
granulocyte-macrophage-CSF, IFNg, KC, monocyte chemotactic protein-1,
macrophage inﬂammatory protein-1a, macrophage inﬂammatory protein-1b,
CCL5, tumor necrosis factora, basic ﬁbroblast growth factor, leukemia inhibitory
factor, chemokine (C–X–C motif) ligand 9 (CXCL9), macrophage inﬂammatory
protein-2, platelet-derived growth factor and vascular endothelial growth factor.
Dendrtic cell preparations
DCs were isolated from the spleen and LNs, as previously described.53 Enriched
DC fractions (typically 495%) were stained with a combination of anti-
CD11c (clone N418), anti-CD205 (clone NLDC145) and anti-CD8 (clone
YTS16.4) to identify resident and migratory subsets. Bone marrow-derived DCs
were generated as previously described using FMS-like tyrosine kinase 3
ligand.33 Anti-CD11c and anti-CD45RA (clone 14.8) were used in combi-
nation to identify conventional (CD11c+CD45RA ) and plasmacytoid
(CD11c+CD45RA+) DC populations. Anti-CD40 (clone FGK-45), anti-CD69
(clone H1.2F3), anti-CD80 (clone 16–10A1), anti-CD86 (clone GL1) and anti-
MHC class II (clone M5/114) expression was determined relative to isotype
control antibodies. ISCOMATRIX adjuvant (5mgml  1), CpG1668 (1mM)
(GeneWorks, Hindmarsh, SA, Australia or Invivogen, San Diego, CA, USA)
or LPS and Escherichia coli serotype 0111:B4 (LPS) (1mgml  1) (Invivogen)
were used to stimulate DCs or macrophages in vitro.F o rin vivo DC activation
marker evaluation or cytokine determinations, mice were injected subcuta-
neously with 3mgo fL P So r5mgo fI S C O M A T R I Xa d j u v a n ti n1 0 0mlo fP B S .
Immunization protocol OVA-speciﬁc CD8+ T-cell and antibody
response
ISCOMATRIX adjuvant was prepared as described previously.54 The vaccine
xantigens were soluble, endotoxin low preparations of chicken OVA
(o0.1EUmg 1) (Worthington Biochemical Corporation, Lakewood, NJ,
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fusion protein was generated by adding the HSV-1 gB CTL epitope SSIEFARL to
the N-terminal of HSV-2 gD glycoprotein (CSL Limited). Alternatively, endotox-
in-low OVA (0.007EUmg 1) was generated at Genentech Inc. from chicken egg-
white (speciﬁc pathogen-free eggs, Charl e sR i v e r ,W i l l m i n g t o n ,M A ,U S A ) ,a s
previously described.55 All prime or boost immunizations were administered
subcutaneously into the scruff of the neck in 100ml of PBS. Each vaccine dose
contained 5mg of ISCOMATRIX adjuvant (equivalent to 3.75 ISCOUNITS) and
30mg of antigen. Mice were terminally bled via cardiac puncture at the time
points indicated. Sera was assayed for reactivity to OVA, as previously described.56
B16 melanoma challenge and adoptive CD8 and non-CD8 cell
transfer
Mice were vaccinated on days  7 and 0 with OVA+ISCOMATRIX adjuvant and
then challenged 7 days after the boost dose with 1 105 B16.F10 melanoma cells
expressing full-length chicken egg OVA (B16-OVA). Tumor-incidence was mon-
itored out to day 125. Tumor-free animals were re-challenged on day 150 with
1 105 parental B16 melanoma (B16-F10) or B16-OVA cells (data not shown).
For adoptive CD8 and non-CD8 cell transfer experiments into naı ¨ve recipients:
the spleens were harvested from donor mice 21 days after the prime-boost vaccine
regimen, and CD8 expressing cells were positively selected using magnetic beads
(Miltenyi Biotec, Auburn, CA, USA). Puriﬁed CD8 (485% purity) and CD8-
depleted cell fractions were adoptively transferred intravenously (10 106)i n t o
naı ¨ve C57Bl6 recipients. After 1 day of the transfer, mice were challenged with
5 105 B16 cells and tumor incidence was monitored. For the therapeutic
melanoma cancer model, all mice were inoculated with 1 105 B16-OVA tumor
cells on day 0. After 5 days of tumor cell inoculation the mice were either
untreated or dosed with ISCOMATRIX, OVA or the ISCOMATRIX vaccine
(adjuvant+antigen), followed by a boost dose on day 12. Tumor volumes were
monitored until the ﬁrst tumor reached 3000mm3, which was nominated as the
survival end-point. 10mgkg 1 of anti-CD40 (clone FKG45, BioXcell, West
Lebanon, NH, USA, o0.14EUmg 1) or control rat IgG2a isotype antibody
(o0.07EUmg 1) were co-administered by intraperitoneal injection on day 5 and
12. For T cell and NK cell depletion experiments; 10mgkg 1 of anti-CD8 (clone
2.43), anti-CD4 (clone GK1.5), anti-asialo-GM1 or anti-NK1.1. (clone PK136,
data not shown) were delivered by intraperitoneal injection on days  7,  4,  1,
+2 and +5 during the day 0, 7 prime-boost vaccine regimen. After 7 days of the
boost dose, all mice were challenged with B16:OVA melanoma cells, as described.
Innate immune cell recruitment and intracellular IFN-c cytokine
staining
To measure the vaccine antigen-speciﬁc CD8+ T-cell response, splenocytes were
cultured ex vivo for 4h in the presence of brefeldin A (5mgml  1)w i t h
SIINFEKL (OVA), SSIEFARL (gB) or an irrelevant peptide (1mgml  1). Brieﬂy,
splenocytes were stained with anti-CD3 (clone 17A2) and anti-CD8 (clone
2.43), washed, ﬁxed and permeabilized (BD Biosciences, Franklin, NJ, USA as
per manufacturer’s instructions) followed by staining with anti-IFN-g (clone
XMG1.2). CD8+ T cells were analyzed by ﬂow cytometry for the expression of
IFN-g.21 To evaluate the recall CD8+ T-cell response, splenocytes were co-
cultured with EG7-OVA cells (a mouse thymoma EL4 cells stably transfected
with OVA) for 5 days. Cells were cultured for a further 4h with brefeldin A,
then stained as described above. Similar results were obtained using the 4-h
ex vivo re-stimulation protocol, although the magnitude of the response was
reduced (data not shown). H2-Kb/Ova-speciﬁc tetramer staining was per-
formed as previously described.57 OVA-tetramer+ CD8+ T cells were also co-
stained for CD44 expression (clone IM7). NK cell IFN-g production was
evaluated in the draining and non-DLNs at the indicated time-points after a
single dose of ISCOMATRIX adjuvant. Brieﬂy, lymphocytes were cultured for
4h in the presence of brefeldin A, before staining with anti-NK1.1 (clone
PK136) and anti-CD49b (clone DX5), and then ﬁxed and intracellular stained
with anti-IFN-g, as described above. CD69 expression was determined on
freshly isolated NK cells, using 7-aminoactinomycin to exclude dead cells.
In vivo CTL assays
Mice were immunized with the ISCOMATRIX vaccine or antigen (OVA) alone
on day  7 and 0. On day 7 mice were injected intravenously with 2 107
CFSEhigh-labeled SIINFEKL peptide-pulsed cells and CFSElow-labeled, control-
unpulsed cells in equal ratios. After 4h spleens were analyzed by ﬂow cytometry
and speciﬁc-lysis was calculated as previously described.13
CD11c-DTR bone marrow chimeras
Recipient C57BL/6 mice were irradiated with two doses of 550cGy 3h apart,
and were reconstituted with 3–5 106 T cell-depleted bone marrow cells
extracted from the femurs and tibias of CD11c-DTR transgenic mice, as
described.29,58 B r i e ﬂ y ,m a t u r eTc e l l sw e r ed e p l e t e df r o mt h ed o n o rb o n e
marrow with anti-CD4 (clone RL172), anti-CD8 (clone 3.168) and anti-Thy1
(clone J1) antibodies, followed by treatment with rabbit complement. After 1
day of reconstitution, mice were injected intraperitoneally with 100mga n t i -
Thy1 (clone T24) to deplete radio-resistant T cells. All antibodies were kindly
provided by Ken Shortman, Walter and Eliza Hall Institute (WEHI). Mice were
rested for 5–7 weeks before use. For systemic DC depletion, chimeras were
injected intraperitoneally with 4ngg body weight diphtheria toxoid (DT) (in
PBS) every 2 days for the duration of the experiment. MHC class II-depleted
splenocytes from Ly5.1 congenic donors were adoptively transferred 24h before
the ﬁrst vaccine dose. The CD8+ T-cell response was comparable when gating
on either transferred Ly5.1 or host Ly5.2 cells (data not shown).
Preparation of CFSE-labeled T cells
OT-I T cells (H-2Kb-restricted anti-OVA257–264) or OT-II T cells (I-Ab-
restricted anti-OVA323–339) were puriﬁed from pooled LNs (inguinal, axillary,
sacral, cervical and mesenteric) of transgenic mice by depletion of non-CD8 T
cells (OT-I) or non-CD4 T cells (OT-II) and were labeled with CFSE as
described.13 The T-cell preparations were routinely 85–95% pure, as deter-
mined by ﬂow cytometry.
Co-culture assays—DCs and OVA-speciﬁc CD8 or CD4 T cells
DC co-culture experiments with transgenic OVA-speciﬁc OT-I (CD8) or OT-II
(CD4) T cells were performed as previously described.13,59 Brieﬂy, enriched
CD11c-expressing DCs were isolated from DLNs following ISCOMATRIX
vaccine or antigen alone (OVA) administration. A total of 5 103 DCs were
co-cultured in Roswell Park Memorial Institute+10% heat-inactivated fetal
bovine serum with 5 104 CFSE-labeled naı ¨ve OT-I or OT-II T cells. Prolifera-
tion was quantiﬁed by ﬂow cytometry after 60h using blank calibration
beads, as described.13 A total of 5 103 highly puriﬁed (by ﬂow cytometry
sorting) (495%) CD8 (CD8+CD205+) MigDC (CD8 CD205+)a n dD N
(CD8 CD205 ) DCs were co-cultured directly ex vivo with CFSE-labeled
OT-I or OT-II cells. Highly puriﬁed (by ﬂow cytometry sorting) (495%)
splenic CD8 or CD4 expressing DCs were pulsed with soluble OVA
(100mgml  1) or OVA+ISCOMATRIX (5mgml  1) for 30min and washed in
media. The indicated number of each DC population was then co-cultured
with CFSE-labeled OT-I or OT-II T cells and proliferation quantiﬁed, as
described above.
Thioglycollate-induced macrophages
Thioglycollate-induced macrophages were generated as previously described.60
Brieﬂy, 1ml of thioglycollate broth was injected into the peritoneal cavity.
Peritoneal cells, (480%) F4/80+ macrophages were isolated in 10ml of
macrophage-serum-free media (Invitrogen).
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